Immunowake, founded with the mission to innovate therapies for patients unresponsive to existing immunotherapies, is a biotechnology company dedicated to advancing cancer treatment. The company focuses on awakening the immune system by overcoming tumor-released suppressive signals. Their core products include the CD3 Bi-specific Platform, which generates bi-specifics to activate T-cells in an antigen-dependent manner, and the VEGF Trap Platform, which has shown significant synergistic anti-tumor effects in vitro. Immunowake targets the oncology market, particularly patients who do not respond to current immunotherapies.

Notable figures affiliated with Immunowake include leading scientists and industry experts in immunotherapy and oncology. The company has attracted investment from prominent venture capital firms specializing in biotech innovations. Key achievements include the development of their proprietary platforms and promising preclinical results demonstrating the efficacy of their therapies. Immunowake's impact lies in its potential to provide new hope for cancer patients who have exhausted other treatment options, thereby addressing a significant unmet need in the medical community.